Cove Street Capital’s Albany Molecular Research Inc AMRI Stock Holding History

Cove Street Capital’s Portfolio AMRI Stock Details AMRI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-60,000	Closed	-$842K	–	94
2017 Q1	$842K	Sell	60,000 -60,000	-50%	-$983K	0.09%	80
2016 Q4	$2.25M	Hold	120,000	–	–	0.24%	58
2016 Q3	$1.98M	Hold	120,000	–	–	0.21%	59
2016 Q2	$1.61M	Hold	120,000	–	–	0.18%	62
2016 Q1	$1.83M	Hold	120,000	–	–	0.24%	65
2015 Q4	$2.38M	Hold	120,000	–	–	0.31%	56
2015 Q3	$2.09M	Hold	120,000	–	–	0.28%	59
2015 Q2	$2.43M	Hold	120,000	–	–	0.29%	57
2015 Q1	$2.11M	Buy	120,000 +20,000	+20%	+$341K	0.28%	57
2014 Q4	$1.63M	Buy	+100,000	New	+$1.84M	0.24%	64

Other funds holding AMRI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

American Capital Management New York $1.86B AUM 20.23% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

CCM

Chicago Capital Management Chicago, Illinois $112M AUM 76.54% 1-Year Est. Return

EWM

Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return

Cove Street Capital's AMRI Position: Q2 2017 in Review

Cove Street Capital sold out of Albany Molecular Research Inc (AMRI) in Q2 2017, closing a stake of 60,000 shares — an estimated $842K sold.

Cove Street Capital first reported a position in AMRI in Q4 2014 and held it in 10 quarters. The position peaked at $2.43M in Q2 2015. 136 funds tracked by Wall St. Rank hold AMRI as of Q2 2017.

Cove Street Capital reported no remaining Albany Molecular Research Inc position as of Q2 2017 after selling out during the quarter.
Cove Street Capital sold 60,000 Albany Molecular Research Inc shares in Q2 2017, an estimated $842K.
Cove Street Capital first reported a position in Albany Molecular Research Inc in Q4 2014 and held it in 10 quarters.
Cove Street Capital's Albany Molecular Research Inc position peaked at $2.43M in Q2 2015.
136 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q2 2017.

Based on Cove Street Capital's 13F filing for Q2 2017, filed 11 Aug 2017.